Our technology has the potential to be applied to a broad number of targets and across a range of tissues and diseases. ValamAi is building a pipeline of promising new first-in-class RNA therapeutics leveraging a next-generation platform technology as we progress our current assets towards the clinic.
ValamAi is currently developing molecules targeting tissue regeneration, immune modulation and precision dermatology across stress urinary incontinence, disc herniation, androgenetic alopecia and oncology. The platform technology is amenable to any nucleotide therapy, and preclinical proof of principle has been established with its lead assets in animal models.
Our most advanced program, VMB-100, has received FDA IND clearance and is working towards Phase IIa initiation in stress urinary incontinence, while the platform is expanded into new indications.
| Indication | Molecule | Discovery | In vitro | In vivo | IND-Study | Ph1 | Ph2 | Ph3 | Market |
|---|---|---|---|---|---|---|---|---|---|
| Stress Urinary Incontinence | VMB-100 |
FDA Cleared
|
|||||||
| Disc Herniation | VMB-100 |
|
|||||||
| Androgenetic Alopecia | VAI-002 |
|
|||||||
| Oncology mRNA + siRNA in 1 |
VAI-003 |
|
|||||||
Stress urinary incontinence is a chronic, debilitating disease affecting 1 in 3 women, with current standard of care limited to physical therapy and highly invasive surgical procedures — there are no FDA-approved therapeutics. Women with SUI are 4–9x more likely to suffer from depression or anxiety, and 88% of severe cases report a significant impact on work. Conservative pricing suggests peak sales potential above $10 billion.
VMB-100, ValamAi's engineered IGF-I mRNA candidate, is delivered by intra-urethral injection into the sphincter muscle. In a rat SUI model (vaginal distention injury), single injections of VMB-100 demonstrated substantial regeneration of the urinary sphincter muscle and dose-dependent improvement in leak point pressure, comparable to or exceeding the positive control. VMB-100 has received FDA IND clearance, with a Phase IIa safety and Phase IIb efficacy & dose-finding study in women with SUI planned for Q1 2027.
Building on the same regenerative mechanism validated in SUI, ValamAi is expanding VMB-100 into disc herniation via intra-disc injection. In a rabbit disc herniation model, treatment reduced the loss of disc height index versus vehicle over 90 days post-injury, supporting further indication expansion of the IGF-I mRNA platform into orthopedic and spine applications.
Topical treatment is strongly preferred over systemic therapy in dermatology, yet topical formulations have historically been limited to small molecules — leaving roughly 85–90% of proteins undruggable by classical small-molecule approaches. ValamAi's VAI-002 is a topical RNA cream in development for androgenetic alopecia (hair loss), part of a broader dermatology strategy that also spans acne, melasma, wrinkles, psoriasis, atopic dermatitis and vitiligo. RNA combined with topical formulation is a novel, largely uncontested niche, with the potential for a faster path to market than systemic RNA therapies.
VAI-003 combines mRNA and siRNA in a single molecule, modulating the local tumor environment through simultaneous upregulation and suppression of different targets in a correctly balanced biological ratio. The biological mechanisms targeted are scientifically validated and apply to solid tumor types where current treatments have limited efficacy, and ValamAi's combinatorial approach aims to bring a solution to difficult-to-treat disease.
The RNA-based therapeutics market is projected to grow from an estimated $6.83 billion in 2023 to $40.81 billion by 2034. To date, the FDA has approved 6 siRNA, 11 ASO and 3 mRNA therapeutics — a proven and fast-growing modality. RNA therapies make every target druggable, and the combination of RNA with topical formulation and dermatology remains a largely uncontested niche with reduced regulatory hurdles relative to systemic therapies.
